Close Menu

NEW YORK (360Dx) – OncoMark on Wednesday announced €2.1 million ($2.2 million) in funding to commercialize its breast cancer diagnostic test.

The Irish diagnostics firm plans to launch the test, called OncoMasTR, in 2018, it said. A biomarker-based prognostic test for early-stage breast cancer, OncoMasTR is aimed at reducing the number of patients who needlessly receive chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.